aTyr Pharma, Inc. (ATYR) Stock Analysis: Exploring a Potential 1,458% Upside in the Biotech Sector
In the ever-evolving landscape of biotechnology, aTyr Pharma, Inc. (NASDAQ: ATYR) emerges as an intriguing prospect for ...
Model output · Signal date 2026-10-15
Atyr Pharma Inc (LIFE) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5111 stocks scored
Rank correlation · 90D
46.0%
Spearman, 122 dates
Market Cap
$2.46B
mid-cap · #29 of 60 peers
Summary
Atyr Pharma Inc (LIFE) stock forecast summary
Our AI ranks Atyr Pharma Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Atyr Pharma Inc is a mid-cap company with a market capitalization of $2.46B. It ranks number 29 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its Net Margin of -32003.7% is the lowest of the 37 peers that report one.
For LIFE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 46.0%, measured on 122 forecast dates between 2026-01-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 164 forecast dates between 2026-01-29 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LIFE included.
Follow LIFE freePrice
LIFE price chart and AI forecast
Cross-section · 2026-10-15
How LIFE ranks among 5111 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Atyr Pharma Inc (LIFE) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | LIFE | Rank |
|---|---|---|
| Market Cap | $2.46B | 29/60 |
| P/B Ratio | 50.46x | 4/50 |
| EPS | $-0.69 | – |
| Book Value/Share | $0.77 | – |
| FCF/Share | $-0.87 | – |
Profitability & Margins
| Metric | LIFE | Rank |
|---|---|---|
| ROE | -124.6% | 42/48 |
| ROA | -87.1% | 48/51 |
| ROIC | -109.3% | 50/53 |
| Operating Margin | -33609.5% | 39/39 |
| Net Margin | -32003.7% | 37/37 |
| EBT Margin | -31765.3% | 41/41 |
Financial Health
| Metric | LIFE | Rank |
|---|---|---|
| Current Ratio | 5.12x | 32/59 |
| D/E Ratio | 0.44x | 24/53 |
| Financial Leverage | 1.43x | 24/52 |
| Interest Coverage | -837.0x | 29/38 |
| Working Capital | $47M | 57/59 |
Cash Flow
| Metric | LIFE | Rank |
|---|---|---|
| Operating Cash Flow | -$55M | 25/57 |
| Free Cash Flow | -$55M | 21/49 |
| Capital Spending | -$280K | 3/49 |
Income Statement
| Metric | LIFE | Rank |
|---|---|---|
| Operating Income | -$64M | 19/54 |
| Net Income | -$61M | 18/51 |
| R&D Expense | $47M | 53/56 |
Dividend & Shareholder Information
| Metric | LIFE | Rank |
|---|---|---|
| Shares Outstanding | 63M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $58M | 83.3% of assets |
| Cash & Short-term Investments | $16M | 23.1% of assets |
| Total Liabilities | $21M | 30.3% of assets |
| Short-term Debt | $8M | 11.6% of assets |
Quarterly Financial Reports
LIFE quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Atyr Pharma Inc (LIFE) industry peers
Companies classified under the same SEC industry code as Atyr Pharma Inc (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LIFE Atyr Pharma Inc | ▲ | $2.46B |
| AMGN Amgen Inc | ▼ | $230.37B |
| GILD Gilead Sciences, Inc. | ▲ | $190.38B |
| MRNA Moderna, Inc. | ▲ | $90.35B |
| ARGX Argenx Se | ▼ | $50.64B |
| RVMD Revolution Medicines, Inc. | ▲ | $41.48B |
| BIIB Biogen Inc. | ▼ | $34.16B |
| BNTX Biontech Se | ▲ | $22.42B |
| EXEL Exelixis, Inc. | ▶ | $15.11B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.82B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.26B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.50B |
| RGEN Repligen Corp | ▶ | $10.06B |
| PCVX Vaxcyte, Inc. | ▲ | $10.05B |
| QGEN Qiagen N.V. | ▶ | $9.88B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.79B |
| TWST Twist Bioscience Corp | ▲ | $9.29B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.88B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B |
| IMVT Immunovant, Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.48B |
| KOD Kodiak Sciences Inc. | ▲ | $5.10B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.86B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.82B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.08B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.74B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.17B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.86B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.44B |
| ADMA Adma Biologics, Inc. | ▼ | $2.40B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.25B |
| NVAX Novavax Inc | ▲ | $2.08B |
| VCEL Vericel Corp | ▲ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| ALVO Alvotech | ▲ | $1.90B |
| MESO Mesoblast Ltd | ▶ | $1.77B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.76B |
| IMCR Immunocore Holdings Plc | ▶ | $1.46B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.46B |
| COAG Hemab Therapeutics Holdings, Inc. | ▼ | $1.40B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.22B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.11B |
| REPL Replimune Group, Inc. | ▲ | $1.07B |
| JATT Zura Bio Ltd | ▶ | $994M |
| VALN Valneva Se | ▼ | $965M |
| IMTX Immatics N.V. | ▲ | $938M |
| MGTX Meiragtx Holdings Plc | ▶ | $904M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $878M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $839M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $798M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $776M |
| SANA Sana Biotechnology, Inc. | ▲ | $698M |
| CADL Candel Therapeutics, Inc. | ▲ | $694M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $674M |
| AURA Aura Biosciences, Inc. | ▲ | $640M |
| SLDB Solid Biosciences Inc. | ▲ | $586M |
| PRME Prime Medicine, Inc. | ▲ | $568M |
| DBVT Dbv Technologies S.A. | ▶ | $525M |
Where LIFE sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Atyr Pharma Inc (LIFE) stock news
ATyr Pharma, Inc. Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In The Journal Of Biological Chemistry
Tyr Pharma, Inc. announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. ATYR0101 is a fusion protein derived from a proprietary ...
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2019 Results - Earnings Call Transcript
Greetings, ladies and gentlemen, and welcome to today's Third Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow ...
FAQ
Atyr Pharma Inc (LIFE) stock forecast FAQ
What is the Atyr Pharma Inc (LIFE) stock forecast?
Our AI ranks Atyr Pharma Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Atyr Pharma Inc stock predictions?
For LIFE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 46.0%, measured on 122 forecast dates between 2026-01-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 164 forecast dates between 2026-01-29 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Atyr Pharma Inc forecasts updated?
Atyr Pharma Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Atyr Pharma Inc's industry peers?
60 issuers in our coverage, LIFE included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.